Cencora, Inc. (NYSE:COR) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Cencora, Inc. (NYSE:COR - Get Free Report) have been given an average rating of "Moderate Buy" by the ten brokerages that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $301.18.

Several equities analysts recently commented on COR shares. Wells Fargo & Company upped their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Citigroup upped their price target on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Robert W. Baird boosted their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. UBS Group lifted their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a research report on Tuesday, April 15th.

Cencora Stock Performance

NYSE:COR traded down $1.50 during trading on Monday, reaching $291.43. The company's stock had a trading volume of 942,182 shares, compared to its average volume of 1,545,004. Cencora has a 12 month low of $214.77 and a 12 month high of $309.35. The firm has a market cap of $56.49 billion, a price-to-earnings ratio of 41.46, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The firm has a 50 day moving average of $280.61 and a 200-day moving average of $256.02. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.80 earnings per share. Research analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a $0.55 dividend. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This trade represents a 4.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock valued at $13,580,967 in the last quarter. Insiders own 10.80% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Net Worth Advisory Group lifted its stake in Cencora by 1.4% in the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after purchasing an additional 36 shares during the last quarter. Obermeyer Wealth Partners grew its position in Cencora by 1.3% during the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after acquiring an additional 36 shares during the last quarter. Cromwell Holdings LLC increased its stake in Cencora by 9.5% in the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after purchasing an additional 39 shares during the period. Pinnacle Wealth Management Advisory Group LLC increased its stake in Cencora by 2.7% in the 1st quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after purchasing an additional 41 shares during the period. Finally, Whittier Trust Co. lifted its position in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after purchasing an additional 44 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.